Fc Fusion Generation Service - Creative Biolabs

Introduction Why Choose Us? FAQs

Accelerate Your Research and Development!

Are you currently facing complex challenges in developing next-generation biotherapeutics or achieving translational success with short-lived molecules? Our Fc Fusions Generation Service helps you obtain stable, customized therapeutic candidates and streamline preclinical development through innovative protein engineering and modular assembly technologies. This significantly de-risks your pipeline and accelerates time-to-market.

Contact our team to get an inquiry now!

The Fc Region as a Versatile Scaffold for Bispecific Antibodies

In the evolving landscape of biotherapeutics, the antibody Fc region has transcended its natural role as an immune effector to become a sophisticated structural scaffold. By leveraging the Fc domain as a homodimeric or heterodimeric backbone, protein engineers can strategically "tinker" with molecular geometry, grafting diverse antigen-binding domains at both the N-terminal and C-terminal ends. This modularity allows for the creation of multi-specific and multi-valent constructs tailored for complex therapeutic mechanisms.

Fc Fusions

The "plug-and-play" nature of the Fc scaffold enables the integration of various binding moieties, including Fabs, scFvs, VHHs, and even non-antibody scaffolds or TCRs. Depending on the desired valency and geometry, several distinct architectures can be achieved:

Standard Fusion Formats: Simple symmetric fusions like scFv-Fc or VHH-Fc mimic the shape of a traditional IgG but replace the Fab with smaller, often more stable, fragments.
Dual-End Fusions: By attaching domains to both ends of the Fc, engineers create "tetravalent" molecules such as scFv-Fc-scFv or VHH-Fc-VHH. These are particularly effective for cross-linking two different cell-surface receptors (e.g., T-cell engagers).
Tandem and Multimeric Designs: Advanced formats like tandem scFv-Fc or Diabody-Fc provide higher avidity and allow for "dual-targeting" of multiple epitopes on the same antigen or different antigens simultaneously.

Creative Biolabs provides a full range of featured Fc Fusion products, including but not limited to:

scFv-Fc	scFv-Fc-scFv
tandem scFv-Fc	VHH-Fc-VHH
Diabody-Fc	……

Therapeutic Advantages of Fc Fusions

Using the Fc region as a central backbone offers several critical pharmacological and industrial benefits that are essential for clinical success:

Superior Pharmacokinetics and Half-life Extension: The most significant advantage is the interaction between the Fc domain and the neonatal Fc receptor (FcRn). This pH-dependent recycling mechanism protects the molecule from lysosomal degradation, extending the serum half-life from hours to weeks.
Enhanced Developability and Purification: The Fc domain serves as a universal "purification tag." These molecules can be efficiently captured using standardized Protein A/G affinity chromatography, which is the industry gold standard. Furthermore, the Fc scaffold often improves the overall solubility and folding stability of the attached binding moieties (like scFvs or Fv), which are otherwise prone to aggregation.
Tunable Effector Functions: The Fc backbone is not a passive tether; it can be "dialed in" based on the therapeutic goal. Engineers can utilize "LALA" (Leu234Ala, Leu235Ala) or "DAPA" mutations to silence immune effector functions (ADCC/CDC) for safety, or conversely, apply Glycoengineering to enhance these functions for more potent tumor cell killing.

Fig. 1 Schematic of the off-the-shelf approach for in vitro production of Fc fusion by protein ligation. (OA Literature) Fig.1 Off-the-shelf approach for in vitro production of Fc fusion by protein ligation.¹

Workflow

Phase 1: In Silico Design & Sequence Engineering
- Format Selection: Choosing between Symmetric or Asymmetric (e.g., Knobs-into-Holes) architectures based on the biological mechanism of action.
- Linker Engineering: Designing flexible or rigid (Proline-rich) linkers to optimize the distance between the Fc and the binding domains (scFv/VHH/TCR), preventing steric hindrance.
- Fc Tailoring: Incorporating mutations for specific goals: Heterodimerization: KiH (Knobs-into-Holes) or electrostatic steering; Effector Silencing: LALA-PG or DAPA mutations to prevent off-target inflammatory responses.
Phase 2: Vector Construction & Cloning
- Gene Synthesis: Sequences are codon-optimized for high expression in mammalian cells and synthesized de novo.
- Vector Insertion: Genes are cloned into high-expression mammalian vectors (e.g., pCDNA3.4 or pCHO).
- Multi-Plasmid Systems: For asymmetric bispecifics, two or more plasmids (e.g., "Knob" chain and "Hole" chain) must be prepared and titrated to find the optimal transfection ratio.
Phase 3: Recombinant Expression & Purification
- Transient & Stable Expression: Rapid prototyping via transient transfection, followed by stable cell line development for lead candidates.
- Optimized Culture Conditions: Fine-tuning feed strategies to minimize proteolysis, a common challenge with fusion proteins.
- Multi-Step Purification: Utilizing Affinity, IEX, and SEC to achieve >95% monomeric purity and eliminate truncated products.
Phase 4: Analytical Characterization & Validation
- Dual-Binding Analysis: Confirmation of simultaneous binding via SPR (Biacore) or BLI.
- Bioactivity Assays: Cell-based assays to verify the potency of the fusion partner (e.g., cytokine-induced proliferation or reporter gene assays).

Why Choose Us?

Creative Biolabs stands at the forefront of protein engineering, specializing in advanced Fc-fusion strategies that are designed for translational success. Our deep expertise and innovative platforms minimize the financial and scientific risks associated with novel biotherapeutic development.

The Creative Biolabs Advantage:

Modular Assembly Expertise: We leverage modular approaches like in vitro Protein Trans-Splicing (PTS) for the rapid assembly of Fc-fusions from domains produced in different optimal hosts. This off-the-shelf approach significantly reduces development time and costs compared to traditional cell-line establishment.
Multivalent Complex Generation: Unlike services limited to standard dimeric Fc fusions, we specialize in engineering advanced formats (e.g., hexameric or multivalent Fc complexes). This is crucial for applications like vaccine development or IVIG replacements, where increased avidity and enhanced FcγR engagement are required for therapeutic effect.
Focus on PK/PD Translation: Our Fc constructs are not just binding verified; they are specifically tested for FcRn binding kinetics under appropriate pH conditions to accurately predict long-term serum half-life and improve in vivo predictability.

Experience the Creative Biolabs Advantage - Get a Quote Today

FAQs

Q: How does the complexity of the therapeutic domain (e.g., multiple disulfide bonds) influence the selection of a suitable expression system for Fc fusion proteins?

A: Domains requiring complex N-linked glycosylation or specialized disulfide bond patterns necessitate mammalian expression systems (CHO, HEK) to provide the correct post-translational modification machinery. For proteins with simpler folding requirements, prokaryotic or yeast systems can offer faster, high-yield production. Regardless of the system, rigorous Quality Control (QC) assays, such as SEC and Mass Spectrometry-based analysis, are essential to confirm structural integrity, purity, and correct folding before any further development.

Q: Scientifically, how do Fc fusion proteins extend half-life compared to chemical modification methods like PEGylation?

A: PEGylation extends half-life primarily by increasing the molecule's hydrodynamic size, thereby hindering renal clearance. In contrast, Fc fusions utilize a biological mechanism: active recycling through the neonatal Fc receptor (FcRn). At acidic pH (in the endosome), the Fc domain binds FcRn, protecting the molecule from lysosomal degradation and recycling it back into the circulation at physiological pH. This biological pathway often results in superior PK profiles and minimizes the risk of reduced target binding affinity sometimes associated with steric modification.

Q: What is the technical rationale and mechanism behind engineering multivalent Fc fusion complexes (beyond the natural dimer) for applications like cellular cross-linking?

A: Multivalency, achieved through specialized engineering techniques (e.g., incorporating the IgM J-chain or designed oligomerization tags), dramatically enhances functional avidity. While intrinsic binding affinity (K_D) may remain the same, the simultaneous binding of multiple therapeutic moieties to cell surface targets results in exponentially stronger and more durable binding. This increase in avidity is critical for inducing cellular cross-linking, enhancing receptor clustering, or boosting immunogenicity (e.g., in vaccine platforms).

Q: What are the key quality metrics and analytical methods used to validate the suitability of an Fc fusion protein for preclinical in vivo studies?

A: Suitability for in vivo studies depends on demonstrating high purity, low endotoxin levels, and confirmed functionality. Essential analytical methods include SEC (to confirm low aggregation and ≥95% purity), SPR or ELISA (to confirm target binding and kinetic data), and specialized FcRn binding assays across the relevant pH range (e.g., pH 6.0 vs. pH 7.4) to accurately predict serum half-life. Endotoxin testing is non-negotiable for injection safety.

Q: What molecular information is necessary for the rational design and successful generation of a novel Fc fusion protein construct?

A: Successful construct design requires the coding sequence of the therapeutic moiety, detailed specifications for the linker (length, sequence, flexibility) to minimize steric clashes between the domains, and the desired Fc isotype (e.g., IgG1 vs. IgG4) to control potential effector function. Furthermore, understanding the functional constraints of the therapeutic moiety is key to selecting the optimal Fc format (dimer, trimer, or hexamer) and expression host.

Reference

Jaakkonen, Anniina et al. "An off-the-Shelf Approach for the Production of Fc Fusion Proteins by Protein Trans-Splicing towards Generating a Lectibody In Vitro." International Journal of molecular sciences vol. 21,11 4011. 3 Jun. 2020, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms21114011

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Related Sections

Online Inquiry

24x7 Service quality

USA

Tel:
Fax:
Email:

UK

Tel:
Email:

Germany

Tel:
Email: